Clin Mol Hepatol.  2019 Sep;25(3):283-293. 10.3350/cmh.2018.0054.

Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir

  • 1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • 2Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
  • 3Yonsei Liver Center, Severance Hospital, Seoul, Korea.


The influence of hepatic steatosis (HS) on chronic hepatitis B (CHB) is unclear. We evaluated the influence of the degree of HS, assessed using the controlled attenuation parameter (CAP) of transient elastography (TE), on treatment outcomes in CHB patients initiated on antiviral therapy.
A total of 334 patients who were initiated on entecavir or tenofovir between 2007 and 2016 with available TE results were recruited.
Of the total study population, 146 (43.7%) patients had HS (CAP > 238 dB/m). Three-hundred-three patients (90.7%) achieved complete virological response (CVR) (hepatitis B virus DNA<12 IU/L), and 25 patients (7.5%) developed hepatocellular carcinoma (HCC). Among hepatitis B e antigen (HBeAg)-positive patients (n=172, 51.5%), 37 (21.5%) experienced HBeAg loss. On univariate analysis, CAP value was not associated with the probability of HCC development (P=0.380). However, lower CAP value was independently associated with higher probability of HBeAg loss among HBeAg-positive patients (hazard ratio [HR]=0.991, P=0.026) and with CVR achievement in the entire study population (HR=0.996, P=0.004). The cumulative incidence of HBeAg loss among HBeAg-positive patients was significantly higher in patients without HS than in those with HS (log-rank, P=0.022).
CAP values were not correlated with HCC development in patients initiated on entecavir and tenofovir. However, CAP values were negatively correlated with the probability of HBeAg loss among HBeAg-positive patients and with CVR achievement.


Fatty liver; Hepatitis B, Chronic; Antiviral agent

MeSH Terms

Carcinoma, Hepatocellular
Elasticity Imaging Techniques
Fatty Liver
Hepatitis B
Hepatitis B e Antigens
Hepatitis B, Chronic*
Hepatitis, Chronic*
Herpesvirus 1, Cercopithecine
Hepatitis B e Antigens
Full Text Links
  • CMH
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: